

**SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 04/17/18**

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage	
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2) Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2) Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2) VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2) Infrainguinal revascular (2) Pediatric VTE (2)	Phase III Phase III Filed 12/17 Phase III Phase III Phase III		
	INVOKANA® (canagliflozin)	Diabetic Nephropathy (2) Reduce the risk of death in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R ) (2)	Phase III Filed 9/17	Phase III Filed 10/17	
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Psoriasis Patient-Controlled Injector	Phase III Filed 3/18	Phase III Phase III	
	SIMPONI ARIA® (golimumab)	Juvenile Idiopathic Arthritis (JIA)	Phase III	Phase III	
	STELARA® (ustekinumab)	Pediatric Psoriasis Ulcerative Colitis	Phase III Phase III	Phase III Phase III	
Infectious Diseases and Vaccines	SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Filed 9/17	Approved 9/17	
	JULUCA® (rilpivirine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Approved 11/17	Positive CHMP Opinion 3/18	
	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Phase III	Phase III	
	pimodivir (JNJ-3872) cadazolid	Influenza A Clostridium difficile-associated diarrhea (2)	Phase III Discontinued	Phase III Discontinued	
Neuroscience	esketamine	Treatment-resistant depression Major depressive disorder with imminent risk for suicide	Phase III Phase III	Phase III Phase III	
	ponesimod	Relapsing multiple sclerosis (2)	Phase III	Phase III	
	paliperidone palmitate 6 month long-acting injectable	Maintenance treatment of schizophrenia	Phase III	Phase III	
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III	
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Filed 11/17	Filed 11/17	
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III	
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III	
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	Phase III	
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III	
		Subcutaneous (SC) formulation (MMY3012) (2)	Phase III	Phase III	
		Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III	
		IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
			Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
	Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)		Phase III	Phase III	
	Previously Treated Adults with Waldenström's Macroglobulinemia with Rituximab (PCYC-1127) (2)		Filed 04/18	Phase III	
	Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)		Phase III	Phase III	
	ERLEADA™ (apalutamide)	Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	Phase III	
		Frontline Chronic graft-versus-host-disease (cGVHD) (2)	Phase III	Phase III	
Prostate cancer non-metastatic castration-resistant		Approved 02/18	Filed 02/18		
Metastatic hormone sensitive prostate cancer		Phase III	Phase III		
Localized prostate cancer		Phase III	Phase III		
apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III		
YONDELIS® (trabectedin)	Relapsed Ovarian Cancer (2)	Discontinued			
ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic	Approved 02/18	Approved 11/17		
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III	
	UPTRAVI® IV	Pulmonary arterial hypertension	Phase III	Phase III	

\* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; SYMTUZA developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with Viiv Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company Ponesimod and Cadazolid developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

**Janssen Pharmaceutical Companies of Johnson & Johnson**  
**Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings\***  
 Selective Highlights as of April 17, 2018

NMEs APPROVED 2017/2018	NMEs IN REGISTRATION	NME PLANNED FILINGS 2018-2021*	
Immunology	Oncology	Oncology	Neuroscience
<b>TREMFYA® (guselkumab)</b> Psoriasis	<b>ERLEADA™ (apalutamide) (EU)</b> Non-metastatic prostate cancer	<b>Imetelstat</b> Myelofibrosis	<b>Esketamine</b> Treatment resistant depression
		<b>Erdafitinib (FGFRI kinase inhibitor)</b> Urothelial cancer	<b>Ponesimod</b> Relapsing multiple sclerosis
<b>Oncology</b>		<b>Niraparib</b> Metastatic castration-resistant prostate cancer (mCRPC)	
<b>ERLEADA™ (apalutamide) (US)</b> Non-metastatic prostate cancer		<b>CAR-T (JNJ-4528)</b> Multiple Myeloma	<b>Infectious Diseases &amp; Vaccines</b>
			<b>Lumicitabine (JNJ-1575)</b> RSV infection
			<b>Pimodivir (JNJ-3872 )</b> Influenza A

\*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Imetelstat licensed from Geron; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; Ponesimod developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson. CAR-T licensed from Legend Biotech.

